Treatment of refractory T‐cell malignancies using gemcitabine
Open Access
- 1 April 2001
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 113 (1) , 185-187
- https://doi.org/10.1046/j.1365-2141.2001.02743.x
Abstract
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.Keywords
This publication has 11 references indexed in Scilit:
- Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 PatientsJournal of Clinical Oncology, 2000
- Gemcitabine in the Treatment of Refractory Hodgkin’s Disease: Results of a Multicenter Phase II StudyJournal of Clinical Oncology, 2000
- Pentostatin in T-cell malignancies – a phase II trial of the EORTCAnnals of Oncology, 1999
- The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemiaBritish Journal of Haematology, 1999
- Treatment of prolymphocytic leukemia with cladribineAnnals of Hematology, 1998
- Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.Journal of Clinical Oncology, 1997
- Comparison of the induction of apoptosis in human leukemic cell lines by 2′,2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinosideLeukemia Research, 1995
- Peripheral/post-thymic T-cell lymphomas: A spectrum of disease clinical, pathologic, and immunologic features of 78 casesCancer, 1990
- T-cell lymphomas: immunologic, histologic, clinical, and therapeutic analysis of 63 cases.Journal of Clinical Oncology, 1988
- Pathologic and Clinical Spectrum of Post-Thymic T-Cell MalignanciesCancer Investigation, 1984